NOTIFICATION OF LATE FILING
|
|
|
|
|
|
|
|
|
|
|
(Check One)
:
|
x
Form 10-K
|
¨
Form 20-F
|
¨
Form 11-K
|
¨
Form 10-Q
|
¨
Form 10-D
|
¨
Form N- SAR
|
|
|
¨
Form N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Period Ended:
|
March 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
Transition Report on Form 10-K
|
|
¨
Transition Report on Form 20-F
|
|
¨
Transition Report on Form 11-K
|
|
¨
Transition Report on Form 10-Q
|
|
¨
Transition Report on Form N-SAR
|
|
For the Transition Period Ended:
|
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
__________________________________________________________________
PART I -- REGISTRANT INFORMATION
Full Name of Registrant : Rasna Therapeutics Inc
Former Name if Applicable
Address of Principal Executive Office
(Street and Number):
420 Lexington Avenue, Suite 2525
City, State and Zip Code : New York, NY 10170
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
|
|
|
|
|
|
|
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
x
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III-- NARRATIVE
State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)
The Company’s Annual Report on Form 10-K for the year ended March 31, 2017 cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to ensure adequate disclosure of certain information required to be included in the Form 10-K. The Company’s Annual Report on Form 10-K will be filed on or before the 15th calendar day following the prescribed due date.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
|
|
|
Tiziano Lazzaretti
|
|
|
|
646-396-4087
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). [X] Yes [_] No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
[ ] Yes [x] No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
__________
_ Rasna Therapeutics Inc____
__________________________
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
Date: June 14, 2017
|
|
By:
|
/s/ Tiziano Lazzeretti
|
|
|
|
|
Tiziano Lazzaretti
|
|
|
|
|
Chief Financial Officer
|
Actavia Life Sciences (PK) (USOTC:RASP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actavia Life Sciences (PK) (USOTC:RASP)
Historical Stock Chart
From Apr 2023 to Apr 2024
